Related Experiment Videos
Statins as cellular antithrombotics
1New York State Department of Health, Wadsworth Center, Albany, NY 12201-0509, USA.
Insights
Statins may prevent cardiovascular events by inhibiting thrombin generation at the cellular level, independent of cholesterol reduction. This suggests statins could be a new class of antithrombotics.
Area of Science:
- Biochemistry
- Cardiovascular Medicine
- Pharmacology
Background:
- Statins reduce cardiovascular disease, but the mechanism beyond cholesterol reduction is unclear.
- Thrombin (IIa) is a key mediator of cardiovascular events, acting via protease-activated receptor-1 (PAR-1).
- Statins inhibit the mevalonic acid pathway, affecting isoprenoid synthesis.
Purpose of the Study:
- To investigate the potential antithrombotic mechanism of statins.
- To explore the role of thrombin (IIa) and protease-activated receptor-1 (PAR-1) in statin action.
- To hypothesize that statins downregulate thrombin generation, acting as antithrombotics.
Main Methods:
- Review of existing literature on statin mechanisms and thrombin signaling.
- Analysis of isoprenoid pathway interactions with PAR-1 activation.
- Hypothesizing cellular mechanisms linking statins, PAR-1, and thrombin generation.
Main Results:
- Statins inhibit an isoprenoid-dependent event between PAR-1 activation and tissue factor upregulation.
- This inhibition occurs upstream of thrombin (IIa) generation.
- Statins impact cell-regulating substances like ras proteins via PAR-1.
Conclusions:
- Statins may exert antithrombotic effects by downregulating thrombin (IIa) generation at the cellular level.
- This mechanism is independent of statins' cholesterol-lowering effects.
- Statins represent a potential novel class of antithrombotic agents.
Abstract:
In clinical trials, statins (vastatins) reduce cardiovascular disease with cholesterol reduction, but this relationship is unclear. We reasoned that (1) thrombin (IIa) is an underlying mediator of cardiovascular events, (2) IIa mediates cellular events through its primary receptor [protease-activated receptor-1 (PAR-1)], and (3) statins inhibit an isoprenoid-dependent event between PAR-1 activation and tissue factor upregulation leading to IIa generation. In the isoprenoid pathways, statins inhibit mevalonic acid synthesis prior to divergence of the cholesterol and other pathway branches, where the latter produce cell-regulating substances (e.g., ras proteins). Through PAR-1 in platelets and other cells, IIa stimulates G-protein-coupled mechanisms including ras proteins. We hypothesize that statins exhibit antithrombotic properties at the cellular level downregulatating IIa generation and that statins may constitute a novel class of antithrombotics.